
2-Butoxyethyl 3-pyridinecarboxylate
Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic with nonivamide's capsaicin activity. Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia. Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed. — DrugBank
- IUPAC-Name
- 2-butoxyethyl pyridine-3-carboxylate
- Summenformel
- C12H17NO3
- Molekulargewicht
- 223.27 g/mol
- Exakte Masse
- 223.12084340 Da
- XLogP3
- 2,1
- Topologische polare Oberfläche
- 48,4 Ų
- Wasserstoffbrücken-Donoren
- 0
- Wasserstoffbrücken-Akzeptoren
- 4
- Kovalente Einheiten
- 1
- Definierte Stereozentren
- 0
Auch bekannt als
16 weitere gemeldete Namen
Kennungen in externen Datenbanken
- ChEBI:CHEBI:32322
- ChEMBL:CHEMBL2105161
- EPA DTXSID:DTXSID4057635
- PubMed:28008281
- PubMed:25929250
- PubMed:19588430
- PubMed:13825636
Am 2026-08-31 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.